{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:01:36Z","timestamp":1790787696299,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Coronary artery lesions including aneurysm, as the most severe complications of Kawasaki disease (KD), remain of great concern. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is implicated in the regulation of inflammatory response and lipid metabolism. Since excessive inflammatory response and aberrant lipid metabolism have involved in the development of KD, we in this study sought to investigate the relationship between coronary artery aneurysm (CAA) and Lp-PLA2 and other blood parameters in children with KD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The participants included 71 KD patients, 63 healthy controls (HCs) and 51 febrile controls (FCs). KD patients were divided into KD-CAA (KD with CAA) group and KD-NCAA (KD without CAA) group. Serum Lp-PLA2 levels were measured using enzyme-linked immunosorbent assays. Other routine clinical parameters were also detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum Lp-PLA2 levels in KD group [4.83 \u03bcg\/mL (3.95\u20136.77)] were significantly higher than those in HC [1.29 \u03bcg\/mL (0.95\u20132.05)] and FC [1.74 \u03bcg\/mL (1.18\u20132.74)] groups. KD-CAA group [5.56 \u03bcg\/mL (4.55\u201322.01)] presented substantially higher serum Lp-PLA2 levels as compared with KD-NCAA group [4.64 \u03bcg\/mL (2.60\u20135.55)]. In KD group, serum Lp-PLA2 level was positively related with erythrocyte sedimentation rate, the levels of leukocytes, platelets, albumin, creatine kinase-MB, and D-dimer, and the <jats:italic>Z-<\/jats:italic>scores of left main CA, right CA, left anterior descending CA, and left circumflex CA; and negatively related with mean corpuscular hemoglobin concentration and mean platelet volume. Moreover, receiver operating characteristic curves showed that Lp-PLA2 exhibited superior and moderate diagnostic performance for distinguishing KD patients from HC and FC ones, respectively, and possessed the potential ability to predict the occurrence of CAAs in KD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lp-PLA2 may be related to KD and the formation of CAAs, and thus may serve as a potential diagnostic biomarker for KD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.854079","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:35:50Z","timestamp":1648708550000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The Relationship Between Lipoprotein-Associated Phospholipase-A2 and Coronary Artery Aneurysm in Children With Kawasaki Disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhenli","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijian","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrrheum.2015.54","article-title":"Kawasaki disease: insights into pathogenesis and approaches to treatment","volume":"11","author":"Shulman","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.jacc.2015.12.073","article-title":"Kawasaki Disease","volume":"67","author":"Newburger","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11926-020-00941-4","article-title":"Kawasaki disease: an update","volume":"22","author":"Rife","year":"2020","journal-title":"Curr Rheumatol Rep."},{"key":"B4","first-page":"178","article-title":"Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children","volume":"16","author":"Kawasaki","year":"1967","journal-title":"Arerugi"},{"key":"B5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/archdischild-2012-302841","article-title":"Management of Kawasaki disease","volume":"99","author":"Eleftheriou","year":"2014","journal-title":"Arch Dis Child."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1161\/CIRCULATIONAHA.105.592865","article-title":"Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease","volume":"113","author":"Kobayashi","year":"2006","journal-title":"Circulation."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals From the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation."},{"key":"B8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41584-020-0426-0","article-title":"Kawasaki disease: pathophysiology and insights from mouse models","volume":"16","author":"Noval Rivas","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1021\/cr200085w","article-title":"Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention","volume":"111","author":"Dennis","year":"2011","journal-title":"Chem Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/med.21597","article-title":"Lipoprotein-associated phospholipase A2: the story continues","volume":"40","author":"Huang","year":"2020","journal-title":"Med Res Rev."},{"key":"B11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/B978-141605469-6.50018-4","article-title":"Role of lipoprotein-associated phospholipase A2 in vascular disease.","volume-title":"Clinical Lipidology","author":"Packard","year":"2009"},{"key":"B12","first-page":"396","article-title":"Modulation of biomarkers of inflammation","author":"Jialal","year":"2009"},{"key":"B13","first-page":"71","article-title":"Chapter six\u2014plasma PAF-AH (PLA2G7): biochemical properties, association with LDLs and HDLs, and regulation of expression.","volume-title":"The Enzymes","author":"Stafforini","year":"2015"},{"key":"B14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2796.2010.02297.x","article-title":"Lp-PLA(2)- a novel risk factor for high-risk coronary and carotid artery disease","volume":"269","author":"Epps","year":"2011","journal-title":"J Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jacl.2017.02.005","article-title":"Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review","volume":"11","author":"Younus","year":"2017","journal-title":"J Clin Lipidol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"100541","DOI":"10.1016\/j.ijcha.2020.100541","article-title":"Relationship of lipoprotein-associated phospholipase A2(Lp-PLA2) and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention","volume":"28","author":"Yin","year":"2020","journal-title":"Int J Cardiol Heart Vasc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.pharma.2015.09.002","article-title":"Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques","volume":"74","author":"Bonnefont-Rousselot","year":"2016","journal-title":"Ann Pharm Fr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4330\/wjc.v7.i10.609","article-title":"Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications","volume":"7","author":"Maiolino","year":"2015","journal-title":"World J Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.trsl.2012.01.013","article-title":"Relationship between adipokines and coronary artery aneurysm in children with Kawasaki disease","volume":"160","author":"Liu","year":"2012","journal-title":"Transl Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3296437","DOI":"10.1155\/2016\/3296437","article-title":"Resistin enhances inflammatory cytokine production in coronary artery tissues by activating the NF-kappaB signaling","volume":"2016","author":"Gao","year":"2016","journal-title":"Biomed Res Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1253\/circj.CJ-66-0096","article-title":"Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013)","volume":"78","author":"Group","year":"2014","journal-title":"Digest version Circ J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00246-009-9599-7","article-title":"Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease","volume":"31","author":"Manlhiot","year":"2010","journal-title":"Pediatr Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/01.ATV.0000160551.21962.a7","article-title":"Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target","volume":"25","author":"Zalewski","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/B978-0-08-097037-0.00066-X","article-title":"Cardiac Markers.","volume-title":"The Immunoassay Handbook","author":"French","year":"2013"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.2174\/1381612820666140622200916","article-title":"Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) bound to LDL and HDL","volume":"20","author":"Tellis","year":"2014","journal-title":"Curr Pharm Des."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3346\/jkms.2014.29.10.1385","article-title":"Association between adipokines and coronary artery lesions in children with Kawasaki Disease","volume":"29","author":"Kim","year":"2014","journal-title":"J Korean Med Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5380792","DOI":"10.1155\/2016\/5380792","article-title":"Metabolic Syndrome and selective inflammatory markers in psoriatic patients","volume":"2016","author":"Vachatova","year":"2016","journal-title":"J Immunol Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1186\/ar2129","article-title":"Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2","volume":"9","author":"Lourida","year":"2007","journal-title":"Arthritis Res Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cardiores.2005.09.015","article-title":"Resistin is secreted from macrophages in atheromas and promotes atherosclerosis","volume":"69","author":"Jung","year":"2006","journal-title":"Cardiovasc Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00125-018-4558-6","article-title":"Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids","volume":"61","author":"Jackisch","year":"2018","journal-title":"Diabetologia."},{"key":"B31","doi-asserted-by":"publisher","first-page":"107303","DOI":"10.1016\/j.carpath.2020.107303","article-title":"The pathology of Kawasaki disease aortitis: a study of 37 cases","volume":"51","author":"Sato","year":"2021","journal-title":"Cardiovasc Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijcard.2020.02.002","article-title":"Hypomethylation of C1q\/tumor necrosis factor-related protein-1 promoter region in whole blood and risks for coronary artery aneurysms in Kawasaki disease","volume":"307","author":"Weng","year":"2020","journal-title":"Int J Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/emmm.201201494","article-title":"Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease","volume":"5","author":"Kentsis","year":"2013","journal-title":"EMBO Mol Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/art.38976","article-title":"Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array","volume":"67","author":"Kuo","year":"2015","journal-title":"Arthritis Rheumatol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.854079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:35:57Z","timestamp":1648708557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.854079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":34,"alternative-id":["10.3389\/fped.2022.854079"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.854079","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"article-number":"854079"}}